National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cladribine (Mavenclad®) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features

Rapid Review Process Complete
Rapid review received 22/08/2017
Rapid review completed 18/09/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended